Millington Financial Advisors LLC Buys 1,773 Shares of Sanofi (NASDAQ:SNY)

Millington Financial Advisors LLC lifted its stake in shares of Sanofi (NASDAQ:SNY) by 9.8% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 19,864 shares of the company’s stock after purchasing an additional 1,773 shares during the quarter. Millington Financial Advisors LLC’s holdings in Sanofi were worth $988,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Rise Advisors LLC boosted its holdings in Sanofi by 98.4% in the 4th quarter. Rise Advisors LLC now owns 506 shares of the company’s stock valued at $25,000 after purchasing an additional 251 shares during the period. Salem Investment Counselors Inc. purchased a new position in Sanofi during the fourth quarter worth about $27,000. Venturi Wealth Management LLC grew its position in Sanofi by 163.5% during the fourth quarter. Venturi Wealth Management LLC now owns 535 shares of the company’s stock worth $27,000 after buying an additional 332 shares in the last quarter. CNB Bank purchased a new stake in shares of Sanofi in the 3rd quarter valued at about $39,000. Finally, Farmers & Merchants Trust Co of Chambersburg PA boosted its position in shares of Sanofi by 115.6% during the 4th quarter. Farmers & Merchants Trust Co of Chambersburg PA now owns 746 shares of the company’s stock valued at $37,000 after acquiring an additional 400 shares during the last quarter. Institutional investors own 10.04% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently weighed in on SNY. Morgan Stanley began coverage on shares of Sanofi in a research report on Tuesday, January 23rd. They set an “equal weight” rating and a $55.00 price objective on the stock. TheStreet cut Sanofi from a “b” rating to a “c” rating in a report on Friday, February 9th. Finally, StockNews.com cut Sanofi from a “strong-buy” rating to a “buy” rating in a report on Tuesday, February 27th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and three have given a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $55.00.

Sanofi Trading Up 1.1 %

Shares of SNY stock traded up $0.54 during trading hours on Tuesday, reaching $47.69. The company’s stock had a trading volume of 1,664,859 shares, compared to its average volume of 1,914,748. The company has a current ratio of 1.27, a quick ratio of 0.87 and a debt-to-equity ratio of 0.19. Sanofi has a one year low of $42.63 and a one year high of $57.82. The stock has a market capitalization of $120.64 billion, a P/E ratio of 20.21, a P/E/G ratio of 1.62 and a beta of 0.61. The firm’s fifty day simple moving average is $47.58 and its 200 day simple moving average is $48.45.

Sanofi (NASDAQ:SNY) last posted its earnings results on Thursday, February 1st. The company reported $0.89 EPS for the quarter, missing the consensus estimate of $0.94 by ($0.05). The company had revenue of $11.76 billion during the quarter, compared to analysts’ expectations of $13.02 billion. Sanofi had a return on equity of 27.47% and a net margin of 12.56%. Equities research analysts expect that Sanofi will post 4.11 EPS for the current year.

Sanofi Increases Dividend

The company also recently disclosed an annual dividend, which will be paid on Thursday, June 6th. Shareholders of record on Friday, May 10th will be given a dividend of $1.478 per share. The ex-dividend date is Thursday, May 9th. This represents a yield of 2.98%. This is a positive change from Sanofi’s previous annual dividend of $1.38. Sanofi’s dividend payout ratio (DPR) is currently 58.47%.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.